When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

DOI: 10.1016/S1474-4422 (25)00199-1 Individual immune cells genetically altered CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system.

CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy was used to combat these rogue B-cells.

People living with autoimmune diseases face nearly twice the risk of developing persistent mental health disorders like depression, anxiety, and bipolar disorder, according to a massive UK-based study ...

Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.

Misbehaving T cells light up long before Parkinson’s symptoms show, zeroing in on vulnerable brain proteins. Their early ...

The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as ...

Individual immune cells genetically altered CIDP is an autoimmune disease in which the immune system’s B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic inflammatory demyelinating polyneuropathy (CIDP).

CIDP is an autoimmune disease in which the immune system's B-cells attack the peripheral nervous system. In the current study, the CAR CD19 T-cell therapy was used to combat these rogue B-cells.